🇺🇸 FDA
Pipeline program

ALLO-329

ALLO-329-101

Phase 1 gene_therapy active

Quick answer

ALLO-329 for Systemic Lupus Erythematosus (With and Without Nephritis) is a Phase 1 program (gene_therapy) at Allogene Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Allogene Therapeutics
Indication
Systemic Lupus Erythematosus (With and Without Nephritis)
Phase
Phase 1
Modality
gene_therapy
Status
active

Clinical trials